Victrex (LON:VCT) Stock Rating Reaffirmed by Credit Suisse Group
Credit Suisse Group restated their outperform rating on shares of Victrex (LON:VCT) in a research report report published on Friday, ThisIsMoney.Co.Uk reports.
Other equities research analysts also recently issued reports about the company. Citigroup reaffirmed a sell rating on shares of Victrex in a report on Thursday, June 18th. Berenberg Bank reduced their target price on Victrex from GBX 2,200 ($27.07) to GBX 2,000 ($24.61) and set a hold rating on the stock in a report on Monday, April 6th. Liberum Capital downgraded Victrex to a hold rating and reduced their target price for the stock from GBX 2,600 ($32.00) to GBX 2,100 ($25.84) in a report on Monday, June 1st. UBS Group reissued a sell rating on shares of Victrex in a report on Tuesday, May 12th. Finally, Barclays reduced their target price on Victrex from GBX 1,690 ($20.80) to GBX 1,660 ($20.43) and set an underweight rating on the stock in a report on Wednesday, June 24th. Four analysts have rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the company. The stock has a consensus rating of Hold and a consensus price target of GBX 1,994.09 ($24.54).
LON VCT opened at GBX 1,990 ($24.49) on Friday. The company has a current ratio of 4.40, a quick ratio of 2.36 and a debt-to-equity ratio of 1.72. The stock’s 50 day moving average is GBX 2,008.80 and its two-hundred day moving average is GBX 2,164.77. The company has a market capitalization of $1.73 billion and a price-to-earnings ratio of 19.40. Victrex has a 1-year low of GBX 1,645 ($20.24) and a 1-year high of GBX 2,574 ($31.68).
Victrex plc, through its subsidiaries, manufactures and sells polymers worldwide. The company offers VICTREX PEEK polymer materials; and biomaterial solutions for use in spine, ortho, dental, trauma, knee, cardiovascular, and orthopedic applications. It also offers specialist solutions for medical device manufacturers.
Recommended Story: Candlestick
Receive News & Ratings for Victrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Victrex and related companies with MarketBeat.com's FREE daily email newsletter.